Owing to ethnicity of the population, those best confirmed polymorphisms in the TLR (toll-like receptor)4 and NOD2 genes with significantly prognostic impact on allogeneic hematopoietic SCT (allo-HSCT) seem to be more applicable to Europeans and are nonpolymorphic in the Asian population. The influence of innate immunity gene polymorphisms on the outcomes of allo-HSCT in those populations has been questioned. We evaluated the influence of 10 candidate single nucleotide polymorphisms (SNPs) in the TLR1, TLR2, TLR3, TLR8 and TLR9 genes on the outcomes of allo-HSCT in a Chinese population including 138 pairs of patients and unrelated donors and a second cohort of 102 pairs of patients and HLA-identical sibling donors. We found that two tagSNPs in the TLR9 gene in the donor side, þ 1174 A/G (rs352139) and þ 1635 C/T (rs352140), influenced the risk of acute GVHD (aGVHD) and CMV reactivation. Furthermore, the presence of the susceptible haplotype (A-C) in donor may be an informative predicator of worse OS at 5 years compared with those with the G-C and G-T haplotypes (58% vs 82.9%, P ¼ 0.024). Our data suggested an unrecognized association between donor TLR9 tagSNPs and the risk of HSCT-related complications in a population without polymorphisms in the TLR4 and NOD2 genes.
INTRODUCTION
The innate immune system consists of two distinct systems. One system is a family of membrane-bound receptors termed toll-like receptors (TLRs), whereas the second family of proteins is called the nucleotide oligomerisation domain (NOD)-like receptors (NLRs). Given its essential role in antimicrobial immunity as well as inflammatory disorders, an extensive body of literature has pointed to the activation of innate immunity via TLRs and NOD2 to be a barrier to induction of transplantation tolerance and be involved in the pathogenesis of GVHD after allogeneic hematopoietic SCT (allo-HSCT). [1] [2] [3] Common polymorphisms in the TLRs and NOD2 genes have been reported to be associated with susceptibility to autoimmune diseases and several infectious diseases. [4] [5] [6] Single nucleotide polymorphisms (SNPs) in the TLR4 and NOD2 genes are most widely studied and have been identified to influence the risk of adverse complications including acute GVHD and invasive aspergillosis after allo-HSCT. [7] [8] [9] However, those best confirmed polymorphisms in the TLR4 and NOD2 genes with significantly prognostic impact on allo-HSCT seem to be more applicable to Europeans and are nonpolymorphic in the Asian population according to data referenced in the GenBank NCBI SNP databases (http://www.ncbi.nlm.nih.gov/snp) and the HapMap database (http://www.hapmap.org). The influence of polymorphisms within innate immunity genes on the outcomes of allo-HSCT in those populations has been questioned.
In the present study, we further investigated the influence of polymorphisms within other innate immunity genes on alloimmune responses in an allo-HSCT cohort from a homogeneous genetic background of the Chinese population. In addition, we attempted to minimize inconsistency of results caused by significant differences in the incidence of transplantation-related complications and outcomes by confirming the analysis in two independent cohorts. The initial cohort consisted of 138 pairs of patients and their unrelated donors (URDs). The second cohort consisted of 102 pairs of patients and their HLAidentical sibling donors.
MATERIALS AND METHODS

Study population and treatment regimen
We unselectively included all patients undergoing allo-HSCT in our Bone Marrow Transplantation Center between January 2001 and March 2009 if donor and patient DNAs were stored in our specimen pool and clinical data were available. The study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University School of Medicine. All the patients and donors gave their written informed consent.
All patients were given fluconazole, norfloxacin and cotrimoxazole for antibiotic decontamination. The main myeloablative conditioning regimen used involved BU/CY (BuCy) without TBI; reduced-intensity conditioning regimens were predominantly fludarabine-based combinations without TBI. On the basis of clinical and animal studies, mycophenolate mofetil as an adjunct to the combination of CSA and methotrexate (MTX) appeared to augment the actions of standard immunosuppressant agents without adding overlapping toxicities. [10] [11] [12] Furthermore, our previous clinical data and animal studies have suggested that low-dose mycophenolate mofetil showed similar immunosuppression without adversely affecting the engraftment. 13, 14 Following this rationale, in our center, patients in both the unrelated and the sibling transplantation cohorts received the same GVHD prophylaxis, consisting of CSA, MTX and low-dose mycophenolate mofetil. CSA was scheduled to be given intravenously at 2.5 mg/kg/day from day À 7, with a target blood level of 200-300 ng/mL. The dosage was tapered during the second month post transplantation, according to the chimeric status and evidence of GVHD. Mycophenolate mofetil was initiated orally at 500 mg/day on day þ 1 and withdrawn on day þ 100. MTX was given at 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3 and þ 6. There were no significant differences in terms of underlying disease, disease status at HSCT, donor-patient gender relationship, conditioning regimen or donor/patient pretransplantation CMV recurrent infection between the URD-and HLA-identical sibling HSCT cohorts. There were only significant differences between the two cohorts in terms of patient age, stem cell source and the dose of CD34 þ cells in graft, and these variables were not identified as significant in univariate or multivariate outcome analysis. Thus, the transplantation characteristics of the two cohorts were very similar and the final analysis of the clinical end points included both cohorts (Table 2) .
SNP selection and genotyping
Genomic DNA was extracted from frozen peripheral blood samples obtained from patients and donors before transplantation using a saltingout method with a commercial DNA extraction kit (Dynal Biotech, Brown Deer, WI, USA), following the manufacturer's recommendations. DNA was quantified using spectrophotometry.
The candidate SNPs in the TLR genes were selected if they met one of the following criteria: (1) SNPs have previously been described to interfere with the TLR signaling pathway and reported to be associated with human diseases; (2) non-synonymous SNPs; and (3) SNPs located outside the coding region at an allele frequency of 420% in the Asian population. SNP nomenclature uses a number that refers to its position in the nucleotide sequence upstream (indicated by a minus sign) or downstream (indicated by a plus sign) of the start of the transcription site, followed by two letters indicating the polymorphism, adenine (A), cytosine (C), guanine (G) or thymine (T). This strategy identified 10 SNPs in the TLR1 gene ( þ 743 C/T, rs4833095; À 216A/G, rs5743565), TLR2 gene (-2098A/C, rs11938228; þ 597 C/T, rs3804099), TLR3 gene ( þ 1234A/G, rs3775291; À 7G/T, rs3775296), TLR8 gene ( þ 1A/G, rs3764880; þ 354 C/T, rs2159377) and TLR9 gene ( þ 1174A/G, rs352139; þ 1635 C/T, rs352140). SNP genotype was determined using multiplex SNaPshot technology, according to previously described methods [15] [16] [17] with the help of an ABI fluorescencebased allelic discrimination method assay (Applied Biosystems, Foster City, CA, USA). The detailed information of primers is available in Supplementary Methods (Supplementary Table S1 ).
Furthermore, to confirm that those polymorphisms in the NOD2 gene with significantly prognostic impact on allo-HSCT are nonpolymorphic in our study cohorts, we genotyped three best known SNPs in the NOD2 gene, [18] [19] [20] namely SNP8 (p.R702W, rs2066844), SNP12 (p.G908R, rs2066845) and SNP13 (p.L1007fs, rs2066847), in our 240 allo-HSCT donors and patients. The detailed information of primers for SNPs in the NOD2 gene is available in Supplementary Methods (Supplementary Table S2 ).
Evaluation of clinical outcome
Acute GVHD (aGVHD) was diagnosed and graded using the established criteria. 21 Given that grade I typically refers to patients with clinically uncertain aGVHD and most clinicians do not treat these patients systemically, only aGVHD of grades II and higher were considered for analysis. Patients who survived X100 days were analyzed for chronic GVHD.
CMV reactivation and disease continued to be important complications post HSCT. As CMV infection is of special concern in the Chinese population and the incidence of asymptomatic infection is high, the episodes of major infection were focused on early CMV infection post HSCT. Surveillance of CMV (pp65 antigenemia) was performed using peripheral blood samples on a weekly basis until day þ 100 and monthly thereafter. According to the published standard criteria, 22 recurrent CMV infection is defined as the new detection of CMV antigenemia or CMV seropositivity (CMV-specific immune globulin M positive, CMV IgM( þ )) in a patient or donor who has had a previously documented infection and who has not had virus detected for an interval of at least 4 weeks during the active surveillance. CMV antigenemia was defined as pp65
Ag-positive cells exceeding 2 cells/50 000 leukocytes using immunohistochemistry analysis. Early CMV infection refers to antigenemia or disease with onset by day 100 after transplantation. Ganciclovir or foscarnet sodium was given for CMV prophylaxis (ganciclovir 10 mg/kg/ day, IV, for 14 days) or pre-emptive treatment pretransplantation. Preemptive therapy was started whenever CMV antigenemia were detected and withdrawn until at least two negative tests were achieved.
Statistical analysis
Linkage disequilibrium analysis among pairs of alleles was performed using the Fisher's exact test. Cumulative incidence using the competing risk method 23 as described by Gray 24 was used to determine the difference in probabilities of aGVHD, chronic GVHD, early CMV infection and relapse in the presence of polymorphisms. OS was estimated using the Kaplan-Meier method. Multivariate Cox regression models using a forward stepwise procedure were applied to analyze the effects of these characteristics and other known clinical and biological factors on HSCT outcomes.
Statistical analysis was performed using the SPSS software version 16.0 and the cmprsk and CumIncidence 23 packages in R (The R foundation, http:// www.R-project.org). All probability values were two-sided. Po0.05 was considered to be statistically significant, and values of P between 0.05 and 0.1 were considered to be indicative of a trend.
RESULTS
Non-association of distribution of TLR polymorphisms with the risk of hematologic malignancies Three best known predictive SNPs in the NOD2 gene in allo-HSCT were monomorphic in our study cohorts, SNP8 ( p.R702), SNP12 (p.G908) and SNP13 (p.L1007), which was in good agreement with data referenced in the GenBank NCBI SNP databases (http:// www.ncbi.nlm.nih.gov/snp) and the HapMap database (http:// www.hapmap.org). The frequencies of TLR genotypes in 240 allo-HSCT donors and patients were similar to the normal population frequencies referenced in the GenBank NCBI SNP databases (http://www.ncbi.nlm.nih.gov/snp). There were no significant differences in the distribution of these genotypes between the URD transplantation cohort and the HLA-identical sibling transplantation cohort. There were also no significant differences in the frequencies of TLR genotypes between patients and their healthy donors (Table 1) . No significant deviations from the expected Hardy-Weinberg genotype frequencies were observed (data not shown). This indicated that TLR polymorphisms do not act as genetic determinants for the risk of developing a hematologic malignancy.
Effect of TLR gene polymorphisms on GVHD When the association of TLR gene polymorphisms with the risk of aGVHD was examined, we found that two SNPs in the TLR9 gene in donor side, TLR9 þ 1174A/G (rs352139) and TLR9 þ 1635 C/T (rs352140), influenced the risk of development of aGVHD. The association was more pronounced in the URD transplantation cohort. Patients receiving stem cells from an URD with the TLR9 þ 1174 variant allele (A allele) experienced grades II-IV aGVHD more frequently than those with the wild-type allele (G allele) (AA/ AG: 49.5% vs GG: 20.7%, Gray's test P ¼ 0.007; Figure 1a ). In contrast, the TLR9 þ 1635 variant allele (T allele) in URDs exerts a protective effect against grades II-IV aGVHD (TT: 16.7% vs CT/CC: 49.1%, Gray's test P ¼ 0.004; Figure 1b) . The same effect was observed in the sibling transplantation cohort, although the incidence of clinically significant aGVHD in this cohort was low overall (12.7%) and the association was not statistically significant (data not shown). The small number of patients with severe aGVHD in the two separate cohorts also precluded statistical analysis of the relationship between these gene polymorphisms and severe aGVHD.
Multivariate Cox regression analysis for aGVHD in the URD transplantation cohort including the donor TLR9 þ 1174 genotype, donor TLR9 þ 1635 genotype and major known risk factors (Table 3) confirmed that an URD with the TLR9 þ 1174 variant allele (A allele) was an independent risk factor for the development of grades II-IV aGVHD (P ¼ 0.009, RR ¼ 3.123, 95% CI, 1.331-7.331). In contrast, an URD with the TLR9 þ 1635 variant genotype (TT) yielded less significantly protective effect (P ¼ 0.067, RR ¼ 3.457, 95% CI, 1.169-10.22). Donor female and patient male gender also significantly contributed to the development of grades II-IV aGVHD (P ¼ 0.04, RR ¼ 1.768, 95% CI, 1.025-3.047). Myeloablative conditioning was found to be a less significant factor (P ¼ 0.061, RR ¼ 3.066, 95% CI, 0.948-9.920). The incidence of aGVHD was not affected by polymorphisms of the TLR1, TLR2, TLR3 or TLR8 genes. No polymorphism was significantly associated with the risk of chronic GVHD, nor were TLR gene polymorphisms from patients.
Effect of TLR gene polymorphisms on early CMV infection
In the present study cohorts, all patients and almost all donors were CMV-seropositive (CMV-specific immune globulin G-positive, CMV-IgG( þ )) before HSCT, and only one donor from the Taiwan Tzu Chi Stem Cells Center was CMV-seronegative. All patients received CMV prophylaxis treatment and those experiencing pretransplantation CMV recurrent infection received pre-emptive treatment. In the URD transplantation cohort, 44 patients (31.88%) experienced recurrent CMV infection pretransplantation, as did 28 patients (27.45%) in the sibling transplantation cohort (Table 2) . Of the total of 240 patients, 134 (55.8%) had experienced early CMV infection with a median onset of 27 days (range 2-64) post HSCT. Of these 134 patients, 28 (20.9%) developed CMV infection during granulocytopenia and 106 (79.1%) did so after neutrophil recovery. The majority of patients developed CMV-positive antigenemia without disease; only nine (6.7%) patients developed CMV disease (seven patients with CMV pneumonia and two with CMV enteritis).
Patients who received stem cells from donors with the TLR9 þ 1635 variant genotype (TT) had a reduced incidence of grades II-IV aGVHD; however, they experienced early CMV infection more frequently than those with the wild-type genotype (CT or CC) in both the URD transplantation cohort (TT: 80% vs CT or CC: 59.3%, Gray's test P ¼ 0.02, Figure 1c ) and the sibling transplantation cohort (TT: 66.7% vs CT or CC: 41.7%, Gray's test P ¼ 0.03, Figure 1d ), although a higher incidence of early CMV infection was There was no significant difference in the impact of TLR1, TLR2, TLR3 or TLR8 SNPs on early CMV infection, nor were TLR polymorphisms from patients (data not shown).
Relapse, OS and risk assessment before allo-HSCT according to donor TLR9 haplotype Kaplan-Meier analysis found no significant associations between donor or patient TLR genotypes and relapse rate. Previous studies have identified that þ 1174 A/G and þ 1635 C/T were the most common SNPs and are regarded as tagSNPs in the TLR9 gene. Furthermore, the TLR9 gene had linkage disequilibrium between the þ 1174 SNP (A or G allele) and the þ 1635 SNP (C or T allele), which can distinguish different haplotypes of TLR9 in the population. Only three haplotypes were observed at reasonable frequencies. In one, þ 1174 A is linked to þ 1635 C (the A-C haplotype), and in others, þ 1174 G is linked to þ 1635 C or T (the G-C or the G-T haplotype). 25 According to our results, TLR9 þ 1174 A and þ 1635 C (the A-C haplotype) are susceptible alleles to aGVHD and whether analysis of these genotypes may be used pre-HSCT to assess risk. In the combined cohort of 240 pairs of donors and patients, we stratified patients according to donor TLR9 haplotypes (A-C, G-C and G-T), defined by SNP at positions þ 1174 and þ 1635, to examine the relative effects of the individual haplotype on OS. Two hundred and ten patients received stem cells from donors with the TLR9 A-C haplotype, and 30 patients received stem cells from donors who are deficient for the A-C haplotype and were homozygous or heterozygous for the G-C and G-T haplotypes. With a median follow-up of 34 months (range 8-113), the presence of the susceptible haplotype (A-C) in donor resulted in worse OS at 5 years compared with those with the G-C and G-T haplotypes. (58% vs 82.9%, log-rank, P ¼ 0.024, Figure 2 ). DISCUSSION TLR9 recognizes and is activated by unmethylated cytosinephosphate-guanine (CpG) dinucleotides, which are relatively common in bacterial and viral DNA but are suppressed and methylated in vertebrate DNA. 26 Activation of TLR9 initiates a cascade of innate and adaptive immune responses, and preclinical and early clinical data support the use of TLR9 agonists in the treatment of patients with solid tumors and hematologic malignancies. 27 In animal model studies, it has become increasingly apparent that the TLR9 pathway has critical roles in the induction of GVHD 28 by interfering with natural Treg function and by promoting the differentiation of Th1 effector T cells. 29 Furthermore, TLR9 signaling of bacterial CpG-DNA is essential for induction of apoptosis and immune cell infiltration in the colon during intestinal GVHD. 30 On the other hand, the TLR9 signal pathway has a key role in viral infection, [31] [32] [33] especially in innate immune defense against mouse CMV infection. 34 Our study found the association of TLR9 tagSNPs in the donors of allo-HSCT with the risk of aGVHD and early CMV infection after allo-HSCT, which may provide clues to support that TLR9 could have a role in human GVHD and CMV infection disease.
TLR9 gene polymorphisms have been reported to be associated with susceptibility to asthma, 25 atopic eczema, 35 systemic lupus erythematosus 36 and clinical course of HIV-1 infection. 37 Elmaagacli et al. 38, 39 reported that an SNP ( À 1486 T/C) in the promoter region of TLR9 influenced TRM rate and relapse rate in patients receiving URD and HLA-identical sibling donor HSCTs, whereas no significant association with aGVHD was identified.
These data suggest that TLR9 genetic polymorphisms correlate with gene function and contribute to the interpatient variability in immune responses. In the present study we found that patients receiving stem cells from URDs who are positive for the TLR9 þ 1174 A or TLR9 þ 1635 C alleles experienced grades II-IV aGVHD more frequently. On the other hand, patients receiving stem cells from donors who are positive for the TLR9 þ 1635 C allele had a reduced incidence of early CMV infection in both the URD transplantation cohort and the sibling transplantation cohort. Our data suggested an interaction between donor TLR9 þ 1174 A and TLR9 þ 1635 C alleles and higher alloreactivities. Although the exact influence of these polymorphisms on TLR9 function and expression is not fully understood, Bochud et al. 37 demonstrated that two SNPs in the TLR9 gene ( þ 1174 A and þ 1635 C) in linkage disequilibrium were associated with the rapid progression of HIV-1 infection. The possible reasons may be that TLR9 signal activation results in the production of inflammatory cytokines and induction of activation and translocation of NF-kB, which can directly enhance HIV-1 replication. [40] [41] [42] Tao et al. 36 found that the þ 1174G allele downregulated TLR9 expression. Taken together, our results may be explained by greater production of TLR9 in patients receiving stem cells from a donor with the TLR9 þ 1174 A and TLR9 þ 1635 C alleles, which is associated with higher TLR9 expression and contributes to the enhancement of alloimmune responses post HSCT.
Interestingly, our study found that only the donor's TLR9 þ 1174 and þ 1635 polymorphism status, and not those of the patient, had significant impacts on the risk of aGVHD and early CMV infection. While the few previously published data about TLR9 in allo-HSCT setting by Elmaagacli et al. 38, 39 suggested the role of the patient's polymorphism status. Possible explanations for those discrepancies are the following. First, TLR9 is expressed not only in certain innate immune cells, including DC subsets, macrophages, monocytes, neutrophils and natural killer cells, but also in activated CD4 þ T cells and B cells. Furthermore, TLR9 has an active role in the proliferation of activated CD4 þ T cells and it modulates suppressive properties of regulatory T cell. 43, 44 As it is known that alloimmune responses are mediated mainly by donor T cells after allo-HSCT, the association between the donor's TLR9 polymorphisms and aGVHD and early CMV infection may become more apparent. Secondly, studies involving different genetic backgrounds of ethnic groups and different SNPs within the TLR9 gene could also contribute to the inconsistencies. Thirdly, some studies have suggested that the TLR9 antitumor activity required TLR9 expression by the tumor itself. 45, 46 Therefore, in the study of Elmaagacli et al., 38, 39 leukemia relapse rate was mainly influenced by the patient's TLR9 polymorphism status.
Although the findings reported here are limited by the number of patients analyzed and needed to be further explored, including the exact influence of these polymorphisms on TLR9 function and expression, our data suggested an unrecognized association between donor TLR9 tagSNPs and the risk of HSCT-related complications in a population without polymorphisms in the TLR4 and NOD2 genes. Current published data implicating the effect of non-HLA immunogenetics on adverse complications of allo-HSCT have been inconsistent. Heterogeneities of patients' characteristics, conditioning regimens and GVHD prophylaxis contribute to these discrepancies. Genetic backgrounds of different ethnic groups could also contribute to the inconsistencies. Transplant patients would thus benefit from construction a risk 'index' of clinical and genetic variables based on ethnic background, which is facilitated by the availability of larger, genetically and clinically more homogeneous study cohort by the growing number of HSCTs in the future. Months after allo-HSCT Figure 2 . OS of patients stratified according to the donor's TLR9 haplotype.
